Trial Profile

Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oregovomab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Pharmacodynamics; Proof of concept
Sponsors Quest PharmaTech

04 Jun 2020 According to a Quest PharmaTech media release, oregovomab Phase 3 clinical trial FLORA-5, is based on this study.
04 Jun 2020 According to a Quest PharmaTech media release, data were recently published (Gynecol Oncol. 2020 Mar;156(3):523-529).
24 Mar 2020 According to an OncoQuest media release, results from this trial were published in Cancer Immunology, Immunotherapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com